Paysign, Inc.(PAYS)— Stock Profile, AI Score & Financials
Industrials · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Paysign, Inc. (PAYS) stock profile, AI quality score, and SEC EDGAR financial data, a Industrials sector company. 13F Pro's AI-powered ranking engine scores PAYS at 74.2/100 on a 32-signal composite quality model, placing it at rank #114 of 2,960 stocks — the top 5% of the AI-ranked universe. PAYS scores in the top quartile across free cash flow (98.6), revenue growth (91.7), earnings quality (89.8). Areas of concern include revenue scale (15.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Paysign, Inc. reports quarterly revenue of $28.3M, net income of $6.8M, free cash flow of $1.2M. Top institutional holders of PAYS by reported 13-F value include Topline Capital Management, BlackRock, PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, based on the most recent SEC filings. PAYS trades on the Nasdaq exchange and files with the SEC under CIK 1496443. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PAYS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Paysign, Inc. directly from SEC EDGAR.
AI Quality Score
74.2/100
AI Rank
#114
Revenue
$28.3M
Net Income
$6.8M
Free Cash Flow
$1.2M
PAYS key financials by period
Paysign, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$82.0M
$7.6M
9.0%
FY 2024
10-K
$58.4M
$3.8M
1.8%
FY 2023
10-K
$47.3M
$6.5M
-0.4%
FY 2022
10-K
$38.0M
$1.0M
0.9%
FY 2021
10-K
$29.5M
$-2.7M
-9.3%
FY 2020
10-K
$24.1M
$-9.1M
-34.6%
Institutions holding PAYS
Institutional investors reporting a position in Paysign, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue rose 48.1% to $28.3M as pharma patient affordability revenue nearly doubled to $14.6M, lifting net income to $6.8M from $1.4M.
Biggest Revenue Drivers
Pharma industry$14.6M+88.9% YoY
Financial benefit of 51 net pharma patient affordability programs launched in the prior twelve months and higher management, setup and claim processing fees
Plasma industry$13.0M+21.4% YoY
Increase in plasma donations and dollars loaded to cards as the market returned to normalized growth, offset by 46 net plasma center reductions
Biggest Revenue Drivers
Total revenue: $28.3M+48.1% YoY
Pharma industry$14.6M+88.9% YoY
Financial benefit of 51 net pharma patient affordability programs launched in the prior twelve months and higher management, setup and claim processing fees
Plasma industry$13.0M+21.4% YoY
Increase in plasma donations and dollars loaded to cards as the market returned to normalized growth, offset by 46 net plasma center reductions
Other$562,398-3.1% YoY
Cardholder fees, interchange, program management, load fees, settlement income and breakage
Within Other
Breakage revenue$75,632
Recorded in other revenue, related solely to the open-loop gift card business
Largest Expense Items
Cost of revenues$10.4M+41.4% YoY
Network and related fees up ~$2,241,000, call center support up ~$784,000 and sales commissions up ~$249,000
Selling, general and administrative$8.5M+4.3% YoY
Compensation up ~$573,000 and stock-based compensation up ~$298,000, offset by a $990,000 gain on contingent consideration fair value
Depreciation and amortization$2.3M+10.4% YoY
Amortization of Gamma acquisition intangibles and continued capitalization of software development costs
Margins: Gross margin expanded to 63.3% from 61.6%, driven primarily by a greater contribution of total revenue from the higher-margin pharma patient affordability business; net margin rose to 23.9% from 7.3%.
Watch Items from the Filing
One pharma patient affordability customer represented 36% of accounts receivable at June 30, 2026, up from 31% at December 31, 2025.
Plasma center count fell by 46 net centers over the prior twelve months as customers closed underperforming centers and one customer moved to another payment provider.
Gamma earn-out written to $0 and terminated; actual revenue was materially below the $20.0 million per-tranche thresholds, producing a $990,000 one-time SG&A gain.
Accounts receivable grew to $103.2M, including $88.8M of pass-through claim reimbursements fully offset in accounts payable.
Effective tax rate fell to 14.5% from 32.1% on stock-based compensation discrete benefits, a driver that may not repeat.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
